FAAH selectively influences placebo effects

Molecular Psychiatry

Volumn 19, Issue 3, 2014, Pages 385-391

  Pecina M ^a   Martinez Jauand M ^b   Hodgkinson, C ^c   Stohler, C S ^d   Goldman, D ^c   Zubieta, J K ^a,e,f  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b Group of Energy Metabolism and Nutrition Department of Fundamental Biology Health Sciences   (Spain)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^d UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cannabinoids; Opioids; PET; Placebo effect

Indexed keywords

ADULT; AFFECT; AMIDOHYDROLASES; BRAIN; FEMALE; FUNCTIONAL NEUROIMAGING; HOMOZYGOTE; HUMANS; MALE; MUTATION, MISSENSE; PAIN MEASUREMENT; PLACEBO EFFECT; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, OPIOID, MU; SYNAPTIC TRANSMISSION; YOUNG ADULT;

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; MU OPIATE RECEPTOR; PLACEBO;

ADULT; ANALGESIA; ARTICLE; BRAIN REGION; DOPAMINERGIC TRANSMISSION; FEMALE; GENETIC VARIABILITY; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PLACEBO EFFECT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 84894559946     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2013.124     Document Type: Article

References (38)

1. Zubieta JK et al. Placebo effects mediated by endogenous opioid activity on muopioid receptors. J Neurosci 2005; 25: 7754-7762
2. Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: Expectation-Activated opioid systems versus conditioning-Activated specific subsystems. J Neurosci 1999; 19: 484-494
3. Kogan NM, Mechoulam R. The chemistry of endocannabinoids. J EndocrinolI Invest 2006; 29(3 Suppl): 3-14
4. Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: Behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 2002; 121: 173-190
5. Gardner EL, Vorel SR. Cannabinoid transmission and reward-related events. Neurobiol Dis 1998; 5(6 Pt B): 502-533
6. Colloca L, Sigaudo M, Benedetti F. The role of learning in nocebo and placebo effects. Pain 2008; 136: 211-218
7. Benedetti F, Amanzio M, Rosato R, Blanchard C. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nat Med 2011; 17: 1228-1230
8. Salio C, Fischer J, Franzoni MF, Mackie K, Kaneko T, Conrath M. CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport 2001; 12: 3689-3692
9. Ledent C et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283: 401-404
10. Welch SP. Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry 2009; 21: 143-151
11. Haller VL, Stevens DL, Welch SP. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase. Eur J Pharmacol 2008; 600: 50-58
12. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002; 296: 678-682
13. Chiang KP, Gerber AL, Sipe JC, Cravatt BF. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: Evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet 2004; 13: 2113-2119
14. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 2008; 65: 220-231
15. Zubieta JK et al. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 2001; 293: 311-315
16. De Vries TJ et al. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 2001; 7: 1151-1154
17. Lesscher HM, Hoogveld E, Burbach JP, van Ree JM, Gerrits MA. Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization. Eur Neuropsychopharmacol 2005; 15: 31-37
18. Hodgkinson CA et al. Addictions biology: Haplotype-based analysis for 130 candidate genes on a single array. Alcohol Alcohol 2008; 43: 505-515
19. Stohler CS, Kowalski CJ. Spatial and temporal summation of sensory and affective dimensions of deep somatic pain. Pain 1999; 79: 165-173
20. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: The PANAS scales. J Pers Soc Psychol 1988; 54: 1063-1070
21. Pollock V, Cho DW, Reker D, Volavka J. Profile of Mood States: The factors and their physiological correlates. J Nervous Mental Dis 1979; 167: 612-614
22. Melzack R, Torgerson WS. On the language of pain. Anesthesiology 1971; 34: 50-59
23. Jewett DM. A simple synthesis of [11C]carfentanil using an extraction disk instead of HPLC. Nuclear Med Biol 2001; 28: 733-734
24. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cerebral Blood Flow Metab 1996; 16: 834-840
25. Narendran R, Martinez D. Cocaine abuse and sensitization of striatal dopamine transmission: A critical review of the preclinical and clinical imaging literature. Synapse 2008; 62: 851-869
26. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 2000; 12: 4038-4046
27. Adcock RA, Thangavel A, Whitfield-Gabrieli S, Knutson B, Gabrieli JD. Rewardmotivated learning: Mesolimbic activation precedes memory formation. Neuron 2006; 50: 507-517
28. Pecina M, Stohler CS, Zubieta JK. Role of mu-opioid system in the formation of memory of placebo responses. Mol Psychiatry 2012; 18: 135-137
29. Cravatt BF et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001; 98: 9371-9376
30. Sim LJ, Selley DE, Xiao R, Childers SR. Differences in G-protein activation by muand delta-opioid, and cannabinoid, receptors in rat striatum. Eur J Pharmacol 1996; 307: 97-105
31. Sim-Selley LJ, Martin BR. Effect of chronic administration of R-()-[2,3-Dihydro-5- methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4- benzoxaz inyl]-(1-naphthalenyl) methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther 2002; 303: 36-44
32. Rice OV, Gordon N, Gifford AN. Conditioned place preference to morphine in cannabinoid CB1 receptor knockout mice. Brain Res 2002; 945: 135-138
33. Mas-Nieto M et al. Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: Evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol 2001; 132: 1809-1816
34. Navarro M et al. Functional interaction between opioid and cannabinoid receptors in drug self-Administration. J Neurosci 2001; 21: 5344-5350
35. Di Marzo V. Targeting the endocannabinoid system: To enhance or reduce? Nat Rev Drug Discov 2008; 7: 438-455
36. Naidu PS, Kinsey SG, Guo TL, Cravatt BF, Lichtman AH. Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. J Pharmacol Exp Ther 2010; 334: 182-190
37. Fattore L, Vigano D, Fadda P, Rubino T, Fratta W, Parolaro D. Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-Administering heroin or WIN 55,212-2. Eur J Neurosci 2007; 25: 2191-2200
38. Fattore L et al. Endocannabinoid system and opioid addiction: Behavioural aspects. Pharmacol Biochem Behav 2005; 81: 343-359.